Allen, Ashley
Vaninov, Natalie
Li, Matthew
Nguyen, Sunny
Singh, Maneet
Igo, Peter
Tilles, Arno W.
O’Rourke, Brian
Miller, Brian L. K.
Parekkadan, Biju
Barcia, Rita N.
Article History
Received: 6 February 2020
Accepted: 22 May 2020
First Online: 23 June 2020
Change Date: 17 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: A.A., N.V., S.N., P.I., A.T., B.O.R., B.L.K.M. and R.N.B. are employees and equity shareholders of Sentien Biotechnologies. B.P. and B.L.K.M. are also equity shareholders and B.P. is an inventor of the technology with licensed patents to Sentien for commercialization. M.S. is a former employee of Sentien Biotechnologies and is at present an employee at Mitobridge, Inc. with no other competing financial interests. M.L. is an inventor of this technology and at present time an employee of Vor BioPharmaceuticals with no other competing financial interests.